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ABSTRACT 
This thesis demonstrates stochastic modelling techniques for the 
quantitative evaluation of the effects of three different pharmacotherapy 
protocols of chronic moderate adult asthma on hospital services (emergency 
room use and hospitalizations). 
The therapies compared were: 1) inhaled beta2-agonist agent and inhaled 
cromolyn; 2) inhaled beta2-agonist agent and an inhaled corticosteroid agent; 
3) inhaled beta2-agonist agent and sustained-release theophylline. 
The combined therapy of an inhaled beta2-agonist agent and an inhaled 
corticosteroid agent had the lowest cost-effectiveness ratio of the three 
treatments indicating it should be the therapy of choice when associated 
hospital costs are included. Even though the inhaled bet~-agonist agent and 
sustained-release theophylline protocol had the lowest maintenance medication 
costs, it also had the highest cost-effectiveness ratio, suggesting it is the least 
desirable therapy when associated hospital services are included in the costs. 
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Asthma is a chronic illness of reversible airway hyperactivity that 
currently affects an estimated 10 million people in the United States. Recent 
evidence suggests that the prevalence and severity of asthma in the United 
States has risen alarmingly. Although asthma is a highly treatable condition 
when properly managed, 43 percent of its economic impact is associated with 
emergency room use, hospitalization, and death. 
Health care planners and physicians should not only be concerned with 
the clinically proven effectiveness of the pharmacotherapy of asthma but also 
with the impact the therapy has on hospital services. This thesis demonstrates 
stochastic modelling techniques for the quantitative evaluation of the effects of 
different pharmacotherapy protocols of chronic moderate adult asthma on 
hospital services, thus providing useful information for the planning of effective 
asthma management strategies. Cost effectiveness ratios were calculated for 
three different therapies, where the costs include not only the medication costs, 
but also the hospital and emergency room costs associated with each treatment. 
The effectiveness measure for each treatment was the time the asthmatic spent 
well (or more accurately, not seeking treatment for an attack or adverse drug 
reaction ). 
The stochastic models for the three different therapies were based on 
probabilities estimated from a meta-analysis of the literature. For each variable 
in the models, sensitivity analysis was pertormed which varied the distribution 
of that variable through a clinically reasonable range. The three treatments 
compared were: 
I. Treatment I: Inhaled beta2-agonist agent (as needed or up to three 
to four times daily) and inhaled cromolyn (two puffs fours times daily), 
2. Treatment 2: Inhaled beta2-agonist agent (as needed or up to three 
to four times daily) and an inhaled corticosteroid agent (two to four 
puffs twice daily), 
ix 
3. Treatment 3: Inhaled beta.-agonist agent (as needed or up to three 
to four times daily) and sustained-release theophylline (dosage must 
be individualized). 
Treatment 1 had an average estimated expected present value of 9270.71 
dollars over a five year time horizon, Treatment 2 had an average estimated 
expected present value of 6236.35 dollars, while Treatment 3 had an average 
estimated expected present value of 21324.18 dollars. 
Patients receiving Treatment 1 spent an estimated average of 98.8 percent 
of the time "well", those receiving Treatment 2 spent an estimated average of 
98.9 percent of the time "well", while Treatment 3 patients spent an estimated 
average of 96 .35 percent "well". 
Treatment 2 has the lowest cost-effectiveness ratio of the three treatments 
indicating it is the therapy of choice when associated hospital costs are 
included. Treatment 3, even though it has the lowest maintenance medication 
costs, has the highest cost-effectiveness ratio suggesting it is the least desirable 
therapy when associated hospital services are included in the costs. 
Given the apparent equivalent therapeutic efficacy of the three 
pharmacotherapy strategies for moderate adult chronic asthma, analysis 
indicates that a betal-agonist and a corticosteroid (Treatment 2) is the 
preferable pharmacotherapy of adult chronic moderate asthma when utilization 
of associated hospital services is considered. A beta2-agonist agent and 
sustained-release theophylline (Treatment 3) is preferred when associated 
hospital services are not considered. The results are sensitive to the probability 
of an emergency room visit and/or hospitalization associated with each 
treatment. 
The models presented make contributions to two fields. To the modelling 
audience, they represent the results of an attempt to synthesize important 
medical and economic factors which play crucial roles in the treatment/cost of 
a chronic disease. To the clinician, the models yield valuable information on 
the comparative cost/effectiveness of therapy combinations. In addition, the 
modelling techniques invite a number of sensitivity analyses which may provide 
new insights conceming the treatment of asthma. 
The methods presented are not intended to provide a definitive answer, 
but rather to demonstrate, within the limitations of any probabilistic model, the 
effects of important parameters on the costs and effectiveness of medical 
treatment plans. The techniques outlined here can be easily applied to other 
diseases such as epilepsy and diabetes. 
As resources available for health cate become increasingly limited, 
difficult choices among competing uses of health care dollars must be made . 
Currently, the standard of care for medical conditions is influenced by 
published clinical trials , consensus among clinicians, and formal peer review 
of medical strategies. Analyses such as those presented herein could be 





Asthma is a chronic illness of reversible airway hyperactivity that 
currently affects an estimated 10 million people in the United States 
(Schoenborn and Marano, 1989). Recent evidence suggests that the prevalence 
and severity of asthma in the United States has risen alanningly (Evans et aJ., 
1987). Between 1980 and 1987, the occurrence of asthma among the general 
population increased 29 percent. During this same period, the asthma 
hospitalization rate increased six percent, and the mortality rate increased 31 
percent (Centers for Disease Control, 1990) . 
The reason for the rise in asthma morbidity and mortality remains 
elusive. However, the physical and emotional toll that asthma takes is 
becoming increasingly clear. A study of the impact of asthma found that during 
1985, adults with asthma missed three million work days, had 4.9 million 
contacts with medical doctors, and required 350,000 hospitalizations (Weiss et 
al.,1992). 
In addition to the human toll, the economic impact of asthma is 
enonnous. The cost of asthma in the United States in 1990 was estimated to 
be $6.2 billion. An estimated 1.81 million people required emergency room 
services for asthma, 52.2 percent of the visits involved persons 18 years old and 
older. Inpatient hospital services represented the largest direct medical 
expenditure, accounting for $1.6 billion, 66 percent of which were for persons 
18 years or older. The estimated impact on production resulting from lost 
school or work days was the largest single indirect cost, approaching $1 billion. 
Although asthma is a highly treatable condition when properly managed, 43 
percent of its economic impact was associated with emergency room use, 
hospitalization, and death (Weiss et al., 1992). The pressing need for more 
efficient allocation of resources in health care has stimulated interest in 
operations research methods. 
B. UTERATURE REVIEW 
A Medline search (1966-1995) was conducted for publications offering 
analyses of asthma health care intelVentions. Medline is an online database 
maintained by the National library of Medicine in Bethesda, Maryland. Several 
combinations of the following entries were used: asthma, costs, cost-analysis, 
cost-effectiveness, Markov. outcomes, model, evaluation, treatment. 
There are hundreds of clinical trials of pharmaceuticals used in asthma 
care that examine outcomes critical to establishing clinical efficacy (i.e., 
changes in pulmonary function), as well as a number of studies of the cost-
effectiveness and cost-benefit of asthma education programs. However, only 
one published study of the cost-effectiveness of asthma pharmacotherapy was 
found, even though this is the main intelVention in asthma. Rutten-van Molken 
et a1. reported on the relative cost-effectiveness of the use of an inhaled betaz-
agonist plus an inhaled corticosteroid versus an inhaled beta2-agonist plus a 
placebo (Rutten-van Molken et aJ. , 1993). This study suggests that the patient-
year savings were seen both in relation to improvements in pulmonary function 
as well as in symptom-free days with the use of an inhaled beta2-agonist plus 
an inhaled corticosteroid in children. Only one study by Ross et aJ. studied the 
cost-effectiveness of asthma therapy in terms of the reduction in the number 
of emergency room visits and hospitalizations (Ross et a1., 1988). In this study, 
a retrospective chart review was undertaken to estimate the costs of treating 
asthma in patients whose treatment plan included cromolyn sodium and those 
whose treatment plan did not include cromolyn (Rosset a1., 1988). 
In 1983, Beck and Pauker described the use of Markov models for 
deciding prognosis in medical applications (Beck and Pauker, 1983) . Since that 
introduction, Markov models have been applied in the medical field with 
increasing frequency. 
Several Markov models examining the clinical strategies for managing 
patients with chronic diseases have been formulated in recent years. A 1994 
study by Disch et at. developed a Markov model comparing the risks and 
benefits of warfarin, quinidine, and amiodarone (phannacotherapy strategies) 
for managing patients with chronic atrial fibrillation (Disch et ai., 1994). 
Estimates for each parameter in the model were extracted from the medical 
literature. The study shows that cardioversion followed by low-dose 
amiodarone to maintain nonnal sinus rhythm appears to be a safe and effective 
treatment for patients with chronic atrial fibrillation. (Disch et ai., 1994) 
Similarly, a 1991 study by Podrid et a1. examined the cost-effectiveness of 
quinidine, procainaimide and mexiletine in the treatment of ventricular 
arrhythmias (podrid et ai., 1991). This study suggests that mexiletine is a cost-
saving alternative therapy for ventricular arrhythmias when adverse reactions 
are considered in addition to phannaceutical costs and treatment efficacy. 
(podrid et ai., 1991) 
A 1990 study by Edelson, Tosteson and Sax used a Markov model to 
research the cost-effectiveness of misoprostol for prophylaxis against 
nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding 
(Edelson et a1., 1990). The model compares prophylaxis treatment with no 
prophylaxis treatment with outcomes of five degrees of gastrointestinal tract 
bleeding. Again, estimates for the parameters were obtained from a review of 
the medical literature. The study found that misoprostol is costly as the primary 
prophylactic therapy for nonsteroidal anti-inflammatory drug-induced 
gastrointestinal tract bleeding, but may be cost-effective as a secondary 
prophylactic therapy in patients with a proven history of gastrointestinal tract 
bleeding. (Edelson et a1., 1990) 
C. PROBLEM DEFINmON 
In recent years operations analysis techniques have become increasingly 
important in the medical community to guide hospital administrators and health 
care providers in the allocation of scarce medical resources. The National 
Institutes of Health (NIH) has published specific guidelines on the management 
of asthma in which several pharmaceutical choices for management exists 
Specifically, for the management of moderate adult asthma, the recommended 
therapy is (NIH expert panel,1991): 
I. Treatment I: Inhaled beta2-agonist agent (as needed or up to three 
to four times daily) and inhaled cromolyn (two puffs four times daily), 
2. Treatment 2: Inhaled beta2-agonist agent (as needed or up to three 
to four times daily) and an inhaled corticosteroid agent (two to four 
puffs twice daily), 
3. Treatment 3: Inhaled beta2-agonist agent (as needed or up to three 
to four times daily) and sustained-release theophylline (dosage must 
be indivjduahzed). 
The Medline search revealed that numerous studies have been conducted 
which -detennine that the above therapies significantly improve pulmonary 
function and are effective in the treatment of asthma, but no comparative 
studies have been conducted to determine the impact of each of the strategies 
on emergency room use or hospitalizations as a measure of effectiveness. 
The objective of this thesis is to develop stochastic models to help 
determine which of the above pharmacotherapy strategies is the most cost-
effective for the asthma management process among adults with chronic 
moderate asthma. The costs for the models are to include daily costs of 
maintenance medication and the expected costs associated with hospital 
services utilization. Then, using the amount of time spent weD (or more 
accurately, the time not seeking treatment for an attack or adverse drug 
reaction) as a measure of effectiveness, a cost/effectiveness ratio can be 
calculated for each of the three strategies. 
D. ORGANIZATION OF THE TIlESIS 
There are five chapters in this thesis Chapter I provides the 
background, selective literature review, and problem definition. Chapter JJ 
describes the disease and its treatment. Chapter III addresses the methodology 
and model formulations. Chapter IV examines the results and Chapter V 
discusses the conclusions. Appendix A contains a glossary of terms. 

11. 'IHE DISEASE AND TREATMENT 
A AS'IHl\llA 
Asthma is characterized by reversible airflow obstruction and airway 
hyperresponsiveness, a condition manifested by an exaggerated 
bronchoconstrictor response to many physical changes and 
chemical/phannacologic agents. Asthma patients develop clinical symptoms 
such as wheezing and dyspnea after exposure to allergens, irritants, viral 
infections, cold air, or exercise. Exacerbations of asthma are acute or subacute 
episodes of progressively worsening shortness of breath, cough, wheezing, 
chest tightness, or some combination of these symptoms. Exacerbations are 
cbaracterized by decreases in expiratory airflow. Bronchial smooth muscle 
contraction is the primary obstructive abnonnality in asthma, causing the 
airways to narrow. However, bronchospasm, mucosal edema, and mucous 
plugging also contribute to the narrowing of the airways. Air is trapped behind 
occluded or narrowed small aitways causing the astbmatic to breathe close to 
hislher total lung capacity leading to hyperventilation . (NIH expert panel, 1991) 
B. PHARMACOTHERAPY 
Asthma therapy has several integral components: patient education, 
environmental control, and phannacotherapy, as well as the use of objective 
measures to monitor the severity of disease and the course of therapy (NIH 
expert panel, 1991). The focus ofthis thesis is on the phannacotherapy of adult 
moderate asthma. Medications for the pharmacotherapy of asthma are ones 
which reverse and prevent airflow obstruction, namely, anti-inflammatory 
agents and bronchodilators Anti-inflammatory agents interrupt the 
development of bronchial inflammation and have a prophylactic and 
suppressive action . Bronchodilators act principally to dilate the airways by 
relaxing bronchial smooth muscle. Although bronchodilators reverse and/or 
inhibit bronchoconstriction and related symptoms of acute asthma, they do not 
reverse bronchial inflammation and hyperresponsiveness. (NIH expert panel, 
1991) 
Since asthma is a disease of the airways, inhalation treatment is 
generally preferable to systemic or oral treatment. The advantage of inhalants 
is that a higher concentration of drug can be delivered more effectively to the 
airways, and systemic side effects are usually avoided. The anti-inflammatory 
agents examined in this thesis are corticosteroids and cromolyn sodium and the 
bronchodilators are betaragonists and theophylline. (NIH expert panel, 1991) 
Pulmonary function tests are essential for diagnosing asthma and 
assessing the severity of asthma in order to make appropriate therapeutic 
recommendations. In analyzing lung function, the vital capacity is the most 
important volume in assessing the severity of the disease. To determine the 
reduction in vital capacity, flow rates are obtained. The volume of air expired 
in one second from maximum inspiration is the forced expiratory volume one 
second (FEV,). Although FEVl is the single best-known measure of pulmonary 
function, correct techniques and calibrated equipment limit its use primarily 
to the physician's office. An alternate measure is the peak expiratory flow rate 
(PEFR), defined as the maximum flow rate that can be generated during a 
forced expiratory maneuver. The PEFR provides a simple , quantitative, 
reproducible measure of airway obstruction that can be obtained at home using 
inexpensive, portable peak flow meters. Individuals 18 years old or older who 
have more than two acute asthma exacerbations per week with a PEFR or 
FEVl decreasing twenty to forty percent from their personal best, are 
considered to have moderate asthma. (NIH expert panel, 1991) 
As mentioned in Chapter I, when treating adult moderate asthma the 
physician has three choices for therapy: 
I. Treatment 1: Inhaled beta2-agonist agent (as needed or up to three 
to four times daily) and inhaled cromolyn (two puffs four times 
daily) , 
2. Treatment 2: Inhaled beta2-agonist agent (as needed or up to three 
to four times daily) and an inhaled corticosteroid agent (two to four 
puffs twice daily), 
3. Treatment 3: Inhaled beta2-agonist agent (as needed or up to three 
to four times daily) and sustained-release theophylline (dosage must 
he individualized). 
All three therapies include a betal-agonist. Betal-agonists are the therapy 
of choice for the treatment of acute exacerbations of asthma and for the 
prevention of exercise- induced asthma. They can be used either intermittently 
to control episodic airway narrowing or chronically to aid in the control of 
persistent airway narrowing. Although beta2-agonists are commonly used 
continuously, a 1990 study by Sears, Taylor, Print, et ai., questions whether 
regular therapy with a specific beta2-agonist may be associated with 
deterioration of control of asthma in some patients (Sears et ai., 1990). A 
study by Tashkin, Conolly, and Deutsch suggests that a potential reason for 
increased asthma symptoms during prolonged therapy with inhaled betaz-
agonists may be a result of the development of tolerance or subsensitivity from 
down-regulation of beta-adrenergic receptors (fashkin et aI, 1982). Adverse 
drug reactions involving the cardiovascular system may also occur as a result 
of inhaled beta2-agonists. 
To avoid frequent fluctuations in PEFR and asthma symptoms, as well 
as the overuse of beta2-agonists, additional therapy is needed. As previously 
specified there are three choices: inhaled corticosteroids, cromolyn sodium, or 
sustained-release theophylline. Inhaled corticosteroids are steroidal anti-
inflammatory drugs effective for the treatment of reversible airflowobstruction . 
Systemic adverse effects of long-term oral steroids are significant and limit 
their use. Adverse effects include Cushing syndrome, cataracts, osteoporosis, 
hypertension and. in rare instances, impaired immune mechanisms. Delivering 
corticosteroids via the airways dramatically reduces the adverse effects. 
However, long-term follow-up studies on the effects of long-tenn high dose 
regimens of inhaled corticosteroids continue. Inhaled cromolyn sodium is a 
non-steroidal anti-inflammatory drug that produces only minimal side effects 
(occasional coughing and dry throat), but its effectiveness in asthma is less 
predictable than that of inhaled corticosteroids Theophylline is an oral 
bronchodilator that, when given as a sustained-release preparation, has a long 
duration of action. It may augment respiratory muscle contractility, reducing 
respiratory muscle fatigue and possibly possesses some degree of anti-
inflammatory activity. However, it has the potential for significant adverse 
effects (nausea, vomiting, tachycardia, arrhythmias, seizures and death) and 
has numerous interactions with other drugs which can either decrease or 
increase the blood level concentration. Because of the severity of toxicity 
associated with theophylline frequent monitoring of serum concentrations (via 
a blood test) must be conducted at regular intetvals which may be viewed as 
detriments to quality of life. (NIH expert panel, 1991) 
Weighing the above competing risks, benefits, and effectiveness 
simultaneously is difficult and involves too many variables for clinical intuition 
alone. For this reason, stochastic models were developed to compare the cost-
effectiveness of the three therapy choices. 
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m. METHODOLOGY AND MODEL FORMUlATIONS 
A. STOCHASTIC APPROACH 
As Chapter I suggests, health care planners and physicians should not 
only be concerned with the clinically proven effectiveness of the 
pharmacotherapy of asthma but also with the impact the therapy has on 
hospital services. This thesis demonstrates stochastic.modelling techniques for 
the quantitative evaluation of the effects of different pharmacotherapy protocols 
of chronic moderate adult asthma on hospital services, thus providing useful 
information for the planning of effective asthma management strategies. In 
this case it is desired to calculate cost effectiveness ratios for three different 
therapies, where the costs include not only the medication costs but also the 
hospital and emergency room costs associated wlth each treatment. The 
effectiveness measure is the time spent well (or more accurately, the time not 
seeking treatment for an attack or adverse drug reaction over a five year time 
period) . 
B. MARKOV MODELS 
1. Discrete-Time Stochastic Model 
Suppose that at any time t an asthmatic is in one of the following states: 
0) asthma well controlled (well): asthmatics in the (well) state are 
experiencing no exacerbation or medication complication 
requiring medical treatment. Patients leave the (well) state when 
either an attack or adverse drug reaction necessitates medical 
attention , 
1) emergency room visit/attack: asthmatics in the (ERJattack) state 
are seeking medical treatment for an asthma attack from the 
emergency room. Patients leave the emergency room visit/attack 
state via admission to the hospital or disposition home, 
2) emergency room visit/ADR: asthmatics in (ERJADR) state are 
seeking medical treatment for an adverse drug reaction (ADR) 
from the emergency room. Patients leave the emergency room 
II 
visit/ADR state via admission to the hospital or disposition home, 
3) hospital/attock: asthmatics in the (hospital/attack) state are 
receiving medical treatment in the hospital for an asthma attack. 
Patients in the hospital/attack state transition to the (well) state 
(i.e., are discharged home), 
4) hospital/ADR: asthmatics in the (hospitaUADR) state are receiving 
medical treatment in the hospital for an adverse drug reaction. 
Patients in the hospitallADR state transition to the (well) state 
(i.e., are discharged home), 
5) minor adversedfllg reaction: asthmatics in the (minor/ADR) state 
are experiencing an adverse drug reaction that requires treatment 
but was discovered during a routine follow-up visit. All patients 
in the minor adverse drug reaction state transition to the (well) 
state. 
The probability of death from an attack or adverse drug reaction is very rare 
among moderate adult asthmatics and therefore is neglected (NIH expert panel, 
1991). As time progresses, the asthmatic moves from state to state with some 
conditional probability. 
Now, assume that the conditional probability of the asthmatic's next state 
(e.g., emergency room visit for an attack) given the entire state history only 
depends upon the present state (Markovian assumption). Further assume that 
the conditional probability of a state does not change over time (the probability 
of going to an emergency room today for an attack is the same as yesterday). 
The assumption of stationary transition probabilities is reasonable in this case 
for a time horizon of five years. However, after this time the overall health of 
the asthmatic could change, a drug tolerance could develop, and other factors 
are likely to occur which may change the conditional probabilities. 
To fonnulate the discrete-time Markov chain model, let X,(k) represent 
the state of the process at time t, when treatment k is used. The Markovian 
assumption above is formally stated as (Howard, 1971), 
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Define 
P(x,<~; ~ i'.l Ix;k) - i" x,~: ~ i'_l' ...• xit) ~ il' xcik)= in> 
= P(Xi~ "' i"1 Ixikl _i,). (1) 
(2) 
so that pjj(k) is the probability that the asthmatic will be in a state j at time t + I 
given an asthmatic on treatment k was in state i at time t. If the asthmatic 
moves from state i during one period to state j during the next period, a 
transition from i to j has occurred. Then, if the patient is in state i at time 
m, the probability that n periods later the patient will be in state j can be 
calculated using the n-step transition probabilities. 
The Pij(k) 's are the transition probabilities for the Markov chain. The 
transition probabilities are displayed as an n x n transition probability matrix 
1"'. 
p (')oo p('lOI pCf)oo PC')e) pC'l(J4 p('los 
pCf) IO pr'\l P('\2 p(!\) pC.l l, p(kl JS 
p (l) 
p(k)20 p(l)21 p('ln prtll) pCklu p ('l~ (3) 
p ('):lO P(J'\1 p(kln p(l))) p (t) ).! pC'\s 
p rkl40 p(kl' l p(kl' 2 pCkl,) pC')« pr')4S 
pCl)~ p(lls l P (')S2 p(k)$) p(k))!>4 p (')ss 
Given that the state at time t is i, the asthmatic must be somewhere in the 
state space at time t + 1. This means that for each 1; (0, I , 2 ..... s), 
(4) 
The discrete-time step should be selected which gives an adequate 
amount of information concerning the amount of time that the asthmatic 
remains in each state. For this model the time step of one day was chosen. 
Since the model projects costs five years into the future, a present-value 
approach is necessary. Present-value analysis is a widely accepted method of 
weighing future dollars by a discount to make them comparable to present 
dollars. Even if all costs, present and future are adjusted for the rate of 
inflation, future costs still need to be discounted. The reason is that a dollar 
not spent now can be invested productively to yield a larger number of real 
dollars in the future (Weinstein and Stason, 1977). 
To formulate the discrete-time cost/effectiveness model, let: 
C,11;!(05) = expected present-value of the cost of treatment k when the 
discount rate is 0, starting in state i. 
a discounting factor for future costs 
D,.!1i) the expected cost of one day sojourn in health state i while 
on treatment k. 
Then, using standard first-step analysis C, rl"\05) can be written as (Howard, 
1971): 
i = 0, ... ,5. (5) 
Expression (5) represents a set of six linear equations that define the 
expected present value of treatment kover an infinite horizon. In matrix form 
the solution to Equation (5) can be written as: 
c(t)«() = (I_P(.t'r l D(t) 
where I is the identity matrix. 
(6) 
To find the expected present value of treatment k over a finite horizon 
(EPVk..'lin,,. ) the follOwing equation is used: 
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(7) 
where N equals the number of time steps for a finite time horizon (e.g., five 
years or 1825 days). 
To estimate the amount of time spent in the (well) state the steady state 
probabilities, '[[a(k) , n/!, 11 2 (/<), n/<J, rr./'J, -;;/k) can be used. The steady state 
probabilities are the lJ'h entry of the limit of the n~step transition probabilities 
defined as' 
(8) 
and can be determined by solving the following set of simultaneous equations 
for each treatment k, (Howard,1971): 
, 




The quantity n/k) gives the fraction of the total amount of time for which the 
asthmatic on treatment k will occupy statej in the long run. Then, using the 
fraction of time the asthmatic occupies the (well) state as the measure of 
effectiveness and the EP'f"ltinlt" costs from Equation (7), a cost-effectiveness 
ratio can be calculated for each of the treatments. 
2. Continuous-Time Stochastic Model 
Since the asthmatic may he seeking treatment at any time, not just at the 
end of a day, a continuous-time model may more accurately represent the 
process. 
Suppose that at any time tan asthmatic is in one of the states described 
15 
above (well, ERJattack, ERiADR, hospital/attack, hospitallADR, minor). Let (/1 
be the transition Tate of the asthmatic from state j to j while on treatment k. 
Symbolically, if X / It) represents the state of the process at t ime t then 
(Howard,1971). 
(10) 
(fhe probability of two or more state transitions is of the order of ( M Y or 
higher and can be neglected if M is sufficiently small) . The infinitesimal 
generator for treatment (fk' has off-diagonal elements Q!!) and diagonal 
elements (Howard, 1971): 
(11) 
Similar to the discrete-time Markov chain cost/effectiveness model define, 
DPt) = the cost per unit time incurred by being in stateiwhile on 
treatment k, 
~(k) (r) = the expected present value (with continuous discounting) 
given the asthmatic starts in state i while on treatment k, 
T fk) time of first transition of {~(It) } while on treatment k, 
the (continuous) discounting factor. 
Then conditional on Xo(lt) = i, TJ and X T/(k) are independent with (Til Xo(lt) 
= i) _ Exp (_Q;; (It)) also, 
(12) 
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thus, conditioning on the first transition state X 1 /') : 
ci'\r);ElfT'D?)e-l'fdti + Ere -tT'l E[ -Qt)]ctJ(r) 
. Q . i~J QI\!) 
=~ 1-~ +-'-E(Qtrl\r) "'[ [ ''']] r r-QAk> r-Q::)I.j 
(13) 
In matrix form, 
and solving gives: 
(14) 
where 0") (r) is the vector of expected present values of treatment k over an 
infinite horizon and 1 is the identity matrix. The expected present values of 
treatment kaver a finite horizon [0, s] is given by: 
C(ll(r) -e-rsp(t)(s)C(t)(r) ~ (l-e -IJp(.tlCs))C(k)(r) 




pk) (t) may be found by the Chapman-Kolmogorov equations as follows. 
Consider the small time intetval [ I, t + M], 
pl\ t+ll.t) = pl)(t)(l-~Q~t).6.t) + ~p?l(t)Q~t) j" 0, ... , 5. (17) 
Substituting Equation (II) in (17) gives 
(18) 
p)tl (t+ll.t) - p)t)(t) " It Pj(klet) Qljt) Ill. (19) 
Dividing by 61 and taking the limit as 6t goes to zero yields 
(20) 
This is a set of six linear constant- coefficient differential equations that relate 
the state probabilities to the transition rate matrix (f'J. In matrix form 
Equation (20) can be written as: 
(21) 
The solution to Equation (21) is pkJ(t) = r' (Hirsch and Smale, 1974). 
Analogous to the discrete-time case, the steady state probabilities are 





Dividing Equation (16) by Equation (22) yields a cost/effectiveness ratio for 
each treatment k. 
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C. ALTERNATIVE FORMULATIONS 
1. Marked Poisson Process Approximation 
An alternative fonnulation of the process is to model non-well episodes 
as sequences of mutually independent random variables with times between 
episodes that are exponentially distributed (a Poisson process). The asthmatic 
experiences periods of continuous satisfactory health that end by a need for 
special medical treatment. During these periods the asthmatic is well. These 
periods often appear "random" ; note that the pattern of randomness may differ 
somewhat between patients on the same treatment, but for the present ignore 
this possibility and let it be modelled as a random variable Tp (k) that represents 
the time between successive events for patient p administered medication k. 
and let successive such times be independently and exponentially distributed: 
p(r;k»r) =e-l(k)' (23) 
where ('J..(k)I1 is the mean time to a next event, following the tennination of 
a state of special medical treatment that interrupts well states; call it the mean 
inter-event time; the parameter I.(k) is also called event rate or hazard rate. 
This parameter is the same as -Q{J(J(/Q in the continuous-time model. 
It is assumed that the event rate or hazard rate },(k) is only dependent 
on the dosage of medication k. However, it is possible to quantify this effect, 
and also account for the effect of covariates or explanatory variables such as 
age, gender, exposure to asthma-attack agents, etc. One technique is to 
represent }. by a Jog-linear function: 
(24) 
where X I< is the dosage per unit time of medicationk, and g( = 1 if male, -1 if 
female, for instance) is a gender-indicator, and a denotes the age of the patient 
(e.g., at the initiation of treatment). Interaction tenns, like P. (xk . a) for 
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treatment.level-age interaction, can also be introduced. This aspect is not 
pursued here, but could be fruitfuL 
There will also be an expense per unit time of using medication k 
during the well periods: C I1lJ (w<lI)' When a well-period-terminating event 
occurs it can be classified into one of the following event types: 
An ER/attack event is defined as a visit to an emergency room for an 
attack. Suppose this event occurs with probability prkl £R(. ".,:A" when "on" 
medication k, independently of all other events or times. From the standpoint 
of time, the duration of an emergency room visit for an attack is on the order 
of hours (fraction of a day); let it have distribution FER(Qttt><!k)(t) with mean 
#1i1l.(. tt. ClI.)' Suppose the cost for a visit to an emergency room for a patient 
prescribed medication k is a random variable C(k) ER(. rr.cJt) with expected cost 
of D' (k) £RMt. cl<). 
An ERJADR event is defined as an emergency room visit for an adverse 
reaction. Let ptKJ ER(ADR) be the probability of such a visit occurring, when taking 
medication k given an event that terminates a well period; assume 
independence as before. Let the duration of an ERJADR visit have distribution 
FER(ADR/t) with mean #ER(ADR). A visit to an emergency room for an adverse 
event has cost Cf'J ER(N.,R) for a patient taking medication k ; let the mean cost 
01<) I!.R(ADR) be D'(/t) H?(ADR) • 
A HospitaUattack event is defined as a visit to a hospital for an attack 
Suppose this event also occurs with probability JII') HO"p(Attock) while on medication 
k , independently of aU other events or times. The duration of a hospital visit 
for an attack is on the order of days; let it have distribution FHOSP(. tt.cl<)(t) with 
mean ,uHo!!p(. tt. ck). Suppose the cost for a visit to a hospital for an attack for a 
patient prescribed medication k is a random variable Ok) Hwp(.a.,'I<) with 
expectation D'!k) HO'I'(ott.ck) • 
A HospitaUADR event is defined as a hospital visit for an adverse 
reaction. Let pM HUSp(ADR) be the probability of such a visit occurring when taking 
medication k, given an event that terminates a well period; assume 
independence. Let the duration of an HospitaUADR visit have distribution 
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F HosP(ADR/t} with mean #Hosp(ADR)' A visit to a hospital for an adverse reaction 
has cost Cf1<.I Hosp(A1JR) for a patient taking medication k; let the mean of 
~) Hosp(ADR) be D'(k) H0'P(AD~ ' 
A Minor/ADR event is defined as an adverse drug reaction discovered 
during a routine follow-up visit. Suppose this event occurs with probability 
p(k) M(ADR) while on medication k, independently of all other events or times. Let 
it have distribution FM(ADR)(t) with mean #M(AD~' Suppose the cost for a 
Minor(ADR for a patient prescribed medication k is a random variable 
CKJM1"DR) with expectation D-(k)M(ADR) 
Since the asthma patient is typically in the well state for time periods 
which are quite long compared to times in other states described, and since any 
of the attack events take, and return, the patient to the well state, it is 
reasonable to simply ignore the durations of the attack events. Therefore, the 
events form a simple Poisson process, which are marked or colored to depict 
event types. Let r be a discounting factor and j = 1,2,3,4,5 represent each 
of the events described above, then, givenn "events" occurring at times T I ' . 
. . , To, they are distributed as n uniform (0, T] order statistics as: 
E[C~.a(r) In events] "tE[e -rrl]EDj'(k)ptl, 
j o t j _: 
(25) 
where Tj - uniform [0, T). So, 
E[C~.a(r)l = r. E[C~.a(r) n events] (),n~ e - i.T 
~ -O n! 
= -h (I -e or') S~ D/(k) p}kl) 0.. n 
"' ~ (I-e-·T) d:.D/KJp}KJ). 
r j _t 
(26) 
Then, adding the costs of using treatment k during the (well) periods, the 
expected discounted costs of treatment k over the period [0, T] is, 
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(27) 
Here ~. is the expected costs of all j events and is given by the solution to the 
following linear equations: 
j " 1, ... ,5. (28) 
To find the expected time unwell (time in all states not zero), the first-passage 
time from state j to state zero (well) satisfies: 
(29) 
which can easily be solved. In the special present case the problem can be 
solved in simple closed form. Now, 
j ~ 1, .. . ,s=5, (30) 
is the duration of an arbitrary unwell period. Note that these alternate with 
well periods. By simple two-state renewal-process theory: 
--'--
E[Fraction o/TIme Well] = ~ 
~+S(k) 
A" 
0 __ ' _ 
I + 1.(k)5 (k) 
(31) 
As before, Equation (27) divided by Equation (31) gives a cosUeffectiveness 
ratio for each treatment k. 
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2. Markov Decision-Analysis 
Another fannutation of the process is that used by Beck and Pauker. In 
1983, Beck and Pauker described the use of Markov processes for deciding 
prognosis (outcome) in medical applications (Beck and Pauker, 1983). Their 
method (Markov decision-analysis) provides a convenient way of modelling 
outcomes for clinical problems with ongoing risk. Analogous to the Markov 
chain model in the previous section, the model assumes that the patient is 
always in one of a finite number of Markov health states. All events of interest 
are modelled as transitions from one state to another. Each state is assigned 
a cost or utility, and the contribution of this cost to the overall outcome 
depends on the length of time spent in that state. The time horizon of the 
analysis is divided into equal increments of time (cycles). During each cycle, 
the patient may make a transition from one state to another. The length of the 
cycle is chosen to represent a clinically meaningful time-interval. 
Evaluation of the process yields the expected amount of time spent in 
each state. The cost that is associated with spending one cycle in a particular 
state is referred to as the incremental cost. Cost accrued for the entire process 
history is the total number of cycles spent in each state, (/3) each multiplied 
by the incremental cost for that state (u3 ) : 
n 
Expected cost .. L t. ".' 
s=t 
(32) 
The probability of making a transition from one state to another during 
a Single cycle are the transition probabilities. 
Sonnenberg and Beck devised a computational method called cohon 
analysis to analyze the model (Sonnenberg and Beck, 1993). Cohort analysis 
begins with 100 percent of a hypothetical population (the cohort) initially in the 
(well) state. For each cycle, the fraction of the cohort initially in each state is 
partitioned among all states according to the transition probabilities. This 
results in a new distribution of the cohort among the various states for the 
subsequent cycle. The cost accrued for the cycle is the cycle sum and is 
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calculated by the formula: 
n 
Cycle sum '" L f.u.> 
s =l 
(33) 
where n is the number of states, ~ is the fraction of the cohort in state s, and 
u. is the incremental cost of state s. The cycle sum is added to a running total 
which is the cumulative cost. The expected cost for the cohort at the end of 
the simulation (a simulated finite time horizon determined by the user) is equal 
to the mean cumulative cost at the end of the simulation divided by the size of 
the cohort. 
The model used was constructed as a decision tree using a Markov cycle-
tree representation to illustrate the process (Hollenberg, 1984), as shown in 
Figure 1. The square represents the decision node and its three branches 
represent the three therapy choices. 
~' •. " ':"._u,. 
--~. 
Figure 1 Decision and State Trees for the Model. 
Each branch leads to the state tree representing the states. The model 
assumes that at all times a patient will be in one of these states and that the 
movement· of the patients from one state to another is dependent only on the 
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present state and is independent of past history (the Markovian assumption). 
Each of the state branches leads to the probability tree which depicts all 
of the possible events that occur during a single cycle of the simulation. 
Figure 2 depicts the probability event tree for the (well) state. These events 
are: 1) exacerbation; 2) adverse drug reaction; 3) no event. An exacerbation 
Figure 2 Probability Event Tree for the (well) state. 
may lead to direct hospitalization or an emergency room visit. An emergency 
room visit may result in a hospitalization. If a patient has an adverse drug 
reaction it may be major (defined as requiring an emergency room visit, 
hospitalization, or both) or minor (defined as discovered during a routine 
follow-up appointment and requiring a cost to treat). Adverse reactions that do 
not incur a cost are not modelled. The label on each terminal branch of the 
cycle tree indicates the Markov health state in which the patient will begin the 
next cycle. For example, whether admitted directly or following an emergency 
room visit, patients admitted to the hospital for an attack will begin the 
subsequent cycle in the "hospitaUattack'· state. Patients seeking treatment for 
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an adverse effect in the emergency room will begin the next cycle in the 
"ER/ADR" state. The model assumes all patients in any "hospital" state (ie., 
HospitaUattack and HospitaUADR) are discharged home. The complete model 
is illustrated in Figure 3. 
~- r.::-
~ 
Figure 3 The Complete Model. 
The costs for each state are weighted by the fraction of patients in that 
particular state and added to a cumulative total. The cumulative total cost at 
the end of the simulation (a simulated finite time horizon determined by the 
user) divided by the cohort size, is equal to the estimated expected cost of 
treating a patient for one time interval (daylweek/month; determined by the 
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transition probabilities). The effectiveness measure is defined in terms of a 
time interval without an exacerbation or therapy complication (herein referred 
to as a Complication Free Interval (CFl) . The effectiveness for each therapy 
is calculated by crediting patients one eFI during each cycle they aTe in the 
(well) state. When weighted by the fraction of patients in that state, this 
results in the estimated expected number of eFTs per patient for each therapy 
regimen. The cost-effectiveness for each therapy is computed by dividing the 
estimated expected cost by the estimated effectiveness. Measures of costs can 
be discounted to account for the decreasing present value of future costs. 
D. DATA AND TRANSmON PROBABILfIY ESTIMATFS 
The transition probabilities for all states are needed to evaluate the 
models. A retrospective chart review was conducted in an effort to obtain these 
probabilities. 
Health charts from asthma patients receiving one of the three therapies 
were identified via a computerized search of pharmacy records at Naval 
Medical Center San Diego (NMCSD), a 600·bed teaching hospital. 
To be included in the study, patients must have met the following 
criteria: (1) an adult eighteen years old or older; (2) moderate asthma is the 
only medical condition; (3) received health care only from NMCSD; (4) a non· 
smoker; (5) on one of the three treatment regimens for at least one year. 
Several assumptions were made. First, although compliance is usually 
less than perfect, it was assumed that all patients complied perfectly with the 
prescribed treatment program. Second, all patients were prescribed 
medications to be taken on an as·needed (PRN) basis. It is not possible to 
ascertain from medical records how often patients use PRN medications. 
Therefore, after consultations with several pharmacists and physicians, it was 
assumed that all patients used PRN medications ten percent of the time. Third, 
since the study only includes adults, it was assumed that all patients were 
knowledgeable about their medications and used them correctly. 
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I. Study Sample 
The review of eligible records yielded 81 qualifying patients, of whom 21 
were in the Treatment 1 group, 30 were in the Treatment 2 group, and 30 were 
in the Treatment 3 group. Characteristics of the study sample by treatment 
groups are compiled in Table 1. The treatment groups did not differ 
significantly (statistically) in age or sex (ANOVA, p-value < 0.05). However, 





































the study sample contains a larger number of females than males 
Epidemiologic data indicate that among children, boys are more likely to have 
asthma (fager, et aI., 1987; Anderson et ai. , 1987). Although the National 
Institute of AUergy and Infectious Diseases (NIAID) Task force concluded in 
1979 that being male is a risk factor for asthma (NIAID, 1979), other reports 
suggest that asthma prevalence either does not differ between adult men and 
women (Broder et ai., 1974; Schachter et ai., 1984) or that adult women 
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predominate in clinic populations (Pedersen and Weeke, 1981). There has been. 
no satisfactory explanation of this apparent discrepancy between epidemiologic 
and clinical results. One possible explanation for the predominance of female 
subjects in this study is that military recruitment standards consider individuals 
with any history of asthma from birth to the present to be disqualified for 
military service (Department of Defense Directive, 1994). Since the Navy 
population is 88 percent male and only a small percentage of males are 
dependent spouses, this may account for the low male incidence count in the 
sample!. Other possible explanations are: a) females may seek medical 
treatment more frequently than males (Gijsbers van Wijk et aJ., 1991), b) 
diagnostic discrepancies are possible between the sexes (Burrows, 1987). 
2. Adverse Drug Reactions 
There were no adverse drug reactions documented for any patient in the 
Treatment 1 group. A total of four adverse drug reactions were recorded in the 
charts for the Treatment 2 group. Oral candidiasis (a fungal infection of the 
mouth) was experienced once by three different patients. All three cases were 
treated in the emergency room. One patient complained of coughing during a 
routine follow-up visit. There were 13 adverse drug reactions associated with 
Treatment 3. Four patients presented to the emergency room with complaints 
of tachycardia. Three patients were treated in the emergency room for gastric 
irritation (dyspepsia I nausea f vomiting), and two patients were seen in the 
emergency room for severe headache (not migraine). Two patients reported 
nervousness, and twO patients reported difficulty sleeping, during a routine 
follow.up visit. Table 2 summarizes the adverse drug reactions of the study 
sample. 
3. Number of Emergency Room Visits 
The 21 patients in the Treatment 1 group visited the emergency room 65 
times. Patients in the Treatment 2 group had a total of 63 visits, and the 










Tx I Tx2 Tx3 
13% 43% 
Table 2. Adverse Reactions from Study Sample. 
Treatment 3 group had a total of 75 emergency room visits. The months of 
March and December had the greatest number of emergency room visits among 
the three groups. These two months represent 26 percent of the emergency 
room visits for all three groups. During the month of December, 54 percent 
of the visits generated by the treatment groups occurred during the week of 
December 20 through December 27. The total number of emergency room 
visits by month are sl,lmmarized in Figure 4. There is a remarkably common 
NumberofER VISits by Month 
MonthofYt'llr 
Figure 4. Number of ER Visits by Month. 
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monthly fluctuation of emergency room visits among all treatments. This is 
most likely attributed tothe level of asthma-attack triggers (e.g., pollens, molds, 
air pollutants , stress , etc. ) during the month. For example, March is a month 
of high emergency room use; it also is a month where the chance of Santa Ana 
winds are high. Santa Ana winds are strong, hot, dry winds that blow off the 
mountains towards the Pacific Ocean and can last for days. Santa Ana winds 
also, typically, have higher levels of pollen, air pollution, dust and other 
irritants, that could lead to higher emergency room use by asthmatics. A 
similar association can be made with stress and the increased emergency room 
use during the month of December. No attempt has been made to incorporate 
effects of seasonality into the models that have been introduced, but this could 
be captured by a time-varying Markov model. 
4. Number of Hospitalizations 
There were no hospitalizations for any patient in any of the treatment 
groups. 
5. Event Probability Estimates 
Data extracted from the charts provide information on events as rates 
( ie., emergency room visit rate, adverse drug reaction rate) . These rates can 
be converted to the corresponding transition probabilities by Equation (34); for 
any constant rate p. the probability of at least one event occurring over a time 
interval of t time units is: 
pet) " 1 - e-I't. (34) 
Equation (34) can be easily understood by examining the survival curve 
for a process defined by a constant rate. The equation describing the survival 
curve is f = e' ,' t, where f is the fraction surviving at time t and p is the 
constant transition rate. At any given time, the fraction that has experienced 
the event is equal to 1 - f Therefore the curve describing the probability that 
at least one event will occur in time t is simply 1 - f, or 1 - e- o' as in Equation 
(34). The probabilities estimated from the study sample are listed in Table 3. 
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Tx I Tx2 Tx 3 
Daily probability ER visit for attack 0.008 0.005 0.007 
Standard Error (0.0006) (0.0005) (0.0004) 
Daily probability ER visit for ADR 0.0004 0.001 
Standard Error (0.0002) (0.0004) 
Daily probability hospital admission for attack 0 
Daily probability hospital admission for ADR 0 
Daily probability of minor AOR 
Table 3. Daily Probabilities Estimated from the Study Sample. 
E. META-ANALYSIS 
Since the transition probabilities are derived from a retrospective chart 
review there is a potential for hias. Patients are not randomly assigned to the 
three treatment groups so it is possible that differences in outcomes could be 
attributed to individual differences among the patients. Administrative pOlicies, 
geographic iocation, and population uniqueness (military), also could impart 
bias. Besides "clinic patient bias' , the data is extracted from patient charts, 
which is solely dependent on the quality of documentation. Furthermore, the 
small sample sizes may not properly represent the entire population. Because 
of these shortcomings, a meta-analysis of published data was conducted to 
estimate each of the variables in the model. 
Meta-analysis refers to a collection of techniques whereby the results of 
two or more independent studies are statistically combined to yield an overall 
answer to a question of interest (Hunter and Schmidt. 1990). Two procedures 
were used to combine data from published clinical trials. The first is a method 
given by Fleiss (Fleiss, 1993). The procedure combines measures of treatment 
difference to an estimator of the common treatment effect. The method 
assumes that the measure of effect size given by each of the studies is the 
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standardized difference between two means: 
y _ XI -X2 
, 
(35) 
where x J and Xz are the means in the two treatment groups and s is the 
square root of the pooled variance. Then an estimator usingvaJues Y J , Y2 ; . 
, . ; Yc from c studies is: 
Ew;Y; 




and n il and n i2 are the sample sizes in each treatment group for the jth study. 
The standard error of Y"' is given by: 
(38) 
Fleiss considers the problem of assessing whether the effect sizes from the 
different studies are homogeneous. The test statistic is: 
(39) 
The hypothesis of homogeneity is rejected if Q exceeds -t!N. u' the 100 (l.u) 
percentile of the chi·square distribution with c·} degrees of freedom. 
The second procedure used is the DerSimonian and Laird (D&L) method 
(DerSimonian and Laird, 1986). In this approach, the parameter of interest in 
each study is the difference between event rates in the treated and control 
groups and is similar to Fleiss. Let d ti and d c, be the number of events in the 
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treated and control groups, respectively, and the corresponding sample size be 




and the rate difference in thei'hstudy is: 
(42) 
with variance estimated by: 
(43) 
A test statistic of homogeneity is: 
. 
Q - i~w;(e/-e,.)l (44) 
where: 
(45) 
To incorporate explicitly any among-study differences which may cause 
variability in treatment effects, such as patient populations, protocols, length 
of follow-up, etc., assume each study has its own treatment effect, OJ ' Let p 
and l: 1 denote the mean and variance of the {lj. A straightforward method of 




Given this estimate, the MOM estimate of the mean effect of treatment (the 








The results of the meta-analysis are summarized in Table 4. Because of the 
limited amount of published data, results from both adult and children studies 
were included. 
F. SUMMARY OF STUDIES USED FOR META-ANALYSIS 
I. Cromolyn 
A retrospective record-based study by Ross et m., to study the effects of 
the inclusion of cromolyn sodium in the regular treatment plan for asthmatic 
patients states that patients in the cromolyn sodium group made three visits to 
the emergency room, where as those in the control group made 54 such visits. 
The number of hospital admissions decreased to one in the cromolyn sodium 
group and seven in the control group (Ross et aJ., 1988). An open drug trial of 
cromolyn in 19 asthmatic children by Mellon et ai., reports a reduction in 
emergency room visits from 24 visits reported by nine of the 16 patients to four 
visits reported by four patients out of 16. The study also reports a reduction in 
hospitalizations from three epjsodcs documented for three patients out of 16 to 
zero episodes (Mellon et aJ., 1982). A double-blind crossover study designed 
to test the effectiveness of cromolyn therapy in children with chronic asthma 
by Hyde et a1., claims a reduetion in hospitalization for asthma exacerbations 
from 38 hospitalizations experienced by 13 patients out of 33 to 12 
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Table 4. Daily Probabilities Estimated from Published Data. 
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hospitalizations reported by seven of the 33 patients (Hyde et ai., 1973). In 
a long-term study by Mascia et a1., who analyzed 53 children with asthma who 
have been taking cromolyn continuously for up to three and one-half years 
found that cromoiyn therapy reduced hospitalizations from 72 percent to 13 
percent (Mascia et aJ., 1976). 
A study by Settipane et a1., evaluated adverse effects thought to be 
associated with cromolyn sodium in all asthmatic patients over a four year 
period (Settipane et ai., 1979). The study reports that the frequency of adverse 
reactions to cromolyn sodium in asthmatic patients was two percent (Settipane 
et a1., 1979). SetcDw et al. compared the efficacy and safety of cromoiyn versus 
theophylline in predominately young, mild to moderate asthmatics (Setcow et 
M., 1983). Tn that study, no adverse reactions were reported by the cromolyn 
group (Setcow et ai., 1983). No adverse reactions to cromolyn were also 
reported by Newth et M., Shapiro et aJ., and Chen et a/. A 1977 double-blind 
comparison of cromolyn and theophylline by Hambleton et M., found that 26 
percent of the asthmatics on the cromolyn therapy experienced mild adverse 
reactions (Hambleton et M., 1977). However, none required treatment with 
another drug (Hambleton et M., 1977). In a double-blind, placebo-controlled 
crossover trial of cromolyn, Mclean et M. found that 15 percent of patients in 
the study reported side-effects to cromolyn (McLean et ai., 1973) . Again, none 
of the reactions required treatment with another drug (McLeanet M., 1973). 
Blumenthal et a1. conducted a double-blind study to detennine the efficacy and 
safety of cromolyn sodium by metered-dose inhaler compared to placebo. Only 
one patient out of 46 (two percent) complained of an adverse reaction (minor 
throat irritation) related to cromolyn (Blumenthal et M., 1988) 
2. Corticosteroids 
In a multi·center, double· blind. randomized, controlled trial by 
Tinkelman et ai., to compare the benefits and adverse reactions of theophylline 
and beclomethasone in children with mild to moderate asthma, it is reported 
that 4.9 percent of children in the beclomethasone group had one or more 
emergency room visits or hospitalizations for asthma (finkelmanet M., 1993). 
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A randomized double-blind multicenter clinical study of the effects of 
corticosteroids and/or betaz-agonists by Van Essen-Zandvlietet aJ., states that 
14 percent of the patients in the betaz-agonist and corticosteroid group visited 
an emergency room for an asthma exacerbation and that there were no 
hospitalizations for asthma exacerbations (Van Essen-Zandvlietet ai., 1992) . 
In a cost-effective analysis of inhaled corticosteroid plus bronchodilator 
therapy, 3.4 percent of patients in the betaz,agonist and corticosteroid group 
were hospitalized fOf asthma (Rutten-van Molkenetal, 1993). A long-tenn 
comparison study of albuterol, theophylline, and bec1omethasone by Meltzer et 
ai., found that 14 percent of patients treated with a betaI-agonist and 
corticosteroid reported exacerbations of asthma (Meltzeret aI, 1992). In a 
randomized double-blind cross-over study comparing the effects of increasing 
the dosage of inhaled corticosteroids in adults with mild to moderate asthma 
by Sears et ai., found that 23 patients out of 32 experienced a total of 70 
asthma exacerbations while on a betaI-agonist and corticosteroid during the 
study (Sears et aJ., 1992). 
A study by Gustafsson et aI , designed to compare the efficacy and safety 
of two inhaled corticosteroids, reports 47 percent of patients receiving 
beclomethasone had adverse events (Gustafssonet aI, 1993). Of those patients 
experiencing adverse reactions, 1.5 percent presented with oral candidiasis 
(Gustafsson et ai., 1993). A review article of corticosteroid aerosols by Tse and 
Bernstein states that bec1omethasone causes major adverse reactions in about 
five percent of patients (Tse and Bernstein, 1984). In a randomized double-
blind cross-over study comparing the effects of increasing the dosage of inhaled 
corticosteroids in adults with mild to moderate asthma by Searset aI, found 
that 6.2 percent of the patients experienced oral candidiasis (Sears et aI, 1992). 
A study of the effects of corticosteroids and/or beta2-agonists by Van Essen-
Zandvliet et ai., states that 28 percent of the patients in the beta2-agonist and 
corticosteroid group reported an adverse effect but none were serious (Van 
Essen-Zandvliet et ai., 1992). In a multi-centered, double-blind, randomized, 
controlled trial by Tinkelman et aJ., to compare the benefits and adverse 
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reactions of theophylline and beclomethasone in children with mild to moderate 
asthma, it is reported that 43.5 percent of patients taking beclomethasone 
experienced adverse reactions (finkelmanetal .. 1993), Of those patients who 
reported adverse drug reactions, 21.3 percent experienced headache, 6.5 
percent experienced gastric irritation, and 1.9 percent reported oral candidiasis 
(Tinkelman et ai., 1993). A long-term comparison study of albuterol, 
theophylline, and beclomethasone by Meltzer et ai., found that 41 percent of 
adverse reactions associated with a beta2-agonist and corticosteroid treatment 
were for headache, 16 percent for nervousness, eight percent for vomiting, and 
16 percent for sleeping difficulties (Meltzer et ai., 1992). 
3. Theophylline 
In a study by Hallas et ai., four out of 11 patients (36 percent) taking a 
beta2-agonist and sustained-release theophylline were admitted to the hospital 
for an asthma attack (Hallas et aJ., 1992). Wood et ai. conducted a study on 
compliance with theophylline therapy among asthmatic children (Wood et ai., 
1979). In their paper it is reported that compliant patients had a mean of 14.5 
emergency visits and 2.4 hospital admissions in the past year (Wood et ai., 
1979). A long-term, double-blind comparison of controlled-release albuterol 
versus sustained-release theophylline in adolescents and adults with asthma by 
Pierson et ai., states that 19 percent of the patients in the theophylline group 
experienced at least one exacerbation that required a short course of oral 
corticosteroids (pierson et ai., 1990). A long-term comparison study of 
albuterol, theophylline, and beclomethasone by Meltzeret ai .. found that 33 
percent of patients treated with a beta2-agonist and theophylline reported 
exacerbations of asthma (Meltzer et aJ., 1992). 
In a multi-centered, double-blind. randomized. controlled trial by 
Tinkelman et ai, to compare the benefits and adverse reactions of theophylline 
and beclomethasone in children with mild to moderate asthma, it is reported 
that 65.7 percent of patients taking theophylline had adverse reactions 
(finkelman et ai .. 1993). Of those patients experiencing adverse reactions, 31.4 
percent reported headaches, and 30.4 percent reported gastric irritation while 
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taking theophylline (Tinkelman et ai., 1993). A long-tenn. double-blind 
comparison of controlled-release albuterol versus sustained-release theophylline 
by Pierson et a/., reports that 23 percent of patients taking theophylline 
exhibited at least one adverse reaction during the study (Pierson et ai. , 1990) . 
The Pierson et a/. study also found that eight percent of the patients reported 
occurrences of headache, 3.2 percent reported nervousness, and 12.9 percent 
reported gastric irritation (Pierson et ai., 1990). Along-term comparison study 
of albuterol, theophylline, and beclomethasone by Meltzer et ai., found that 44 
percent of adverse reactions associated with a betaragonist and theophylline 
treatment were for headache. 15 percent for nervousness, 21 percent for 
vomiting, and 10 percent for sleeping difficulties (Meltzer et ai., 1992). 
G. TRANSmON PROBABILfIY MATRICES 
Substituting the probabilities extracted from the literature into Equation 
(3) yields the daily transition probability matrices] for each of the treatments . 
.991 .005 .001 • 001 .001 .001 
.999 0 .001 0 0 
p { l ) .999 0 .001 
.370 .630 0 
.530 .470 
0 
.992 .003 .001 .001 .001 .002 
.999 0 .001 0 
pP) .999 0 .001 
.370 .630 0 
.530 .470 
'Pmbabj]jtie~ for Hosp ital/attacK and HOlIpit ' L'ADR . !.Otes bMed on mean 2.69 and 1.89 day hospital stay 
re'p"ctfully. du n ng FY9~ . u t racted fmm th~ R~tros.,., cti"" c"..,·Mix Analysi. System (RCMAS) 
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.916 .010 .005 .005 .003 .001 
.999 .001 0 




Costs are counted in the model by associating a specific cost with each 
state. The cost for each state is: 
0) Well: cost of one day supply of medication 
1) ER/attack: MEPRS! cost of an ER visit for NMCSD 
2) ERJADR: MEPRS cost of an ER visit for NMCSD 
3) Hospital/attack: MEPRS cost of mean 2.69 day hospital stay2 
4) HospitaVADR: MEPRS cost of mean 1.89 hospital stay2 
5) MinorJADR: expected cost of one day supply of medications to 
treat reaction. 
Table 5 lists the costs per day used in the models. 
'M~dlcal E"Pens~ and Performance Reporting System (MEPRS). A computer based program designed to 
renectw\cOS\$OfServlCesmcludmgpersonnei,dlrect e ><p cnsc •• anddcprecilllion 
'Mean hospital stay based on fiscal yca r 1994 data ~><fn)ct~d from th~ Jlctrospectiv~ Cas e·Mix Analys;s System 
(RCMAS) 
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Tx 1 Tx2 Tx3 
Wen 2.16 0.60 0.26 
ER/attack 140 140 140 
ER/ADR 140 140 140 
HospitaUattack 557 557 557 
HospitaUADR 529 529 529 
Minor/ADR 0.83 0.83 0.83 
Table 5. Daily Costs used in t,he Models. 
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IV. RESULTS 
A. MODEL INPUTS 
All models were evaluated according to the transition probabilitie!'i estimated 
in Chapter III from a meta-analysis of the literature . The discount rate used was five 
percent and the length of time was five years (1825 days). AJ1 calculations except for 
the cohort analysis were performed with the assistance of MAPLE V Release 3 
computer software and the cohort analysis was programmed using Turbo Pascal for 
DOS version ZOcomputer software 
The cohort analysis was started with 1000 hypothetical patients in the Asthma 
Well Controlled (well) state. Every day (one cycle for the analysis) the patients are 
newly re-distributed among the six states (Well, ER/attack, ER/ADR, Hospital/attack, 
Hospital/ADR, Minor/ADR) according to the transition probabilities estimated in 
Chapter III from a meta-analysis of the literature. 
For each variable in the models, sensitivity analysis was perionned which 
varied the distribution of that variable throughout the range listed in Table 4 and the 
analysis was repeated for each value within that range. 
B. OUTCOMES 
Table 6 displays the estimated expected present value of Treatments 1. 2, and 
3, for each of the models . All four models resulted in nearly identical values with 
A" 
Analysis 
Tx 1 9141.68 9141.04 9258.54 9141.59 9170.71 29.27 
Tx 2 621"7.56 6217.12 6293 .09 6217.63 6236.35 18.91 
Tx3 21125 .2 1 21123.7:1 21922.69 21125.08 21324.18 199.50 
Table 6. Estimated Expected Present Value Over a Five Year Period. 
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Treatment 1 (a beta2-agonist and a corticosteroid) as the therapy with the lowest 
estimated expected present value costs when associated hospital services are included. 
Table 7 lists the estimated effects of Treatment I, Treatment 2, and Treatment 
3 on the proportion of time spent "well" for each of the models. All four models again 
gave nearly identical numerical values with Treatment 1 accumulating a slightly 
higher proportion of time in the "well" state over a five year time horizon. 
Discrete 
Tx 1 0.988 
Tx2 0.989 
Tx 3 0.964 











Table 7. Estimated Proportion of Time Spent "well". 




Dividing the daily expected present value by the proportion of time spent "well" 
yields the cost/effectiveness ratio. The cost/effectiveness ratios for each of the 
treatments are summarized in Table 8. 
Discrete Continuous Marked A"" Sid Error 
Analysis 
Tx 1 5.069 5.069 5.135 5.069 5.085 0.0165 
Tx 2 3.445 3.445 3.486 3.445 3.449 0.0102 
Tx 3 12.000 12.000 12.499 11.995 12.123 0.1251 
Table 8. Cost-Effectiveness Ratios. 
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Treatment 2 has the lowest cost-effectiveness ratio of the three treatments 
indicating it is the therapy of choice when associated hospital costs are included. 
Treatment 3, even though it has the lowest maintenance medication costs, has the 
highest cost-effectiveness ratio suggesting it is the least desirable therapy when 
associated hospital services are included in the costs. 
The estimated present value costs of each treatment were compared to the 
estimated present value if costs associated with the emergency room use and 
hospitalizations were excluded . A summary of the comparison is illustrated in Figure 
5. 
ltl~ oflncJ.uctingversus Net 1nc1~ &ems 
Figure 5. Impact on Costs of IndudingfExciuding Events. 
c. SENSITIVny ANALYSIS 
The analysis results in a higher cost-effectiveness ratio for Treatment 1 than 
Treatment 2. However. the maintenance costs of Treatment 1 are 3.5 percent higher 
than Treatment 2. It is of interest to examine if reducing the maintenance costs 
associated with Treatment 1 would reduce its cost-effectiveness ratio to a point where 
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it would become the preferred treatment. The maintenance costs (costs of a 30 day 
supply of medication) for Treatment 1 were reduced by five percent to 50 percent 
incrementally by five percent, and the cost-effectiveness ratios re-calculated. Figure 
6 displays the results. 
Impact of Reducing Maintenance Costs for Treatment 1 






o L-_~_~_~_~_~_~_~ _ ___ _ 
% Reduction in Maintenance Costs 
Figure 6. Impact of Reducing Maintenance Costs of Treatment 1. 
Although reducing the maintenance costs for Treatment I by 50 percent lowers 
its cost-effectiveness ratio,to 4.11, it is still higher than the 3.44 cost·effectiveness ratio 
of Treatment 2. 
In an effort to determine the contribution of the cost of each individual event 
to the cost·effectiveness ratio, analysis was pertormed separately with each individual 
costs in turn set to zero, thus removing that cost from the model. The combined 
analysis found that regardless of which event had the cost removed from the model, 
Treatment 2 remained the preferred therapy. Treatment 2 also remained the preferred 
therapy when the discount factor was varied from five percent to 25 percent. 
However. cost-effectiveness ratios were sensitive to the probability of an emergency 
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room visit or hospitalization. Therefore, the cost-effectiveness ratios were re-
calculated varying the probabilities for emergency room visits/hospitalizations 
The probability of visiting an emergency room for an attack while on Treatment 
2 was varied from zero to five percent and the cost-effectiveness ratios re-calculated. 
The results are shown in Figure 7. When the probability for an ER visit for an attack 
is 2.5 percent, the cost-effectiveness ratio for Treatment 2 increases to 6.18, which is 
Impact of Varying Probability of an ER Visit for 
an Attack for Treatment 2 
0.02 0.025 0.03 
.----
------------ ---
Probability of an ER Visit for an Attack 
Figure 7. Impact of Varying Probability ER/Attack of Treatment 2. 
greater than the cost-effectiveness ratio for Treatment 1 (5.06). Therefore, if the daily 
probability of a visit to the ER for an attack while on Treatment 2 is 2.5 percent then, 
keeping all else the same, Treatment 1 would be the preferred treatment. The 
probability for an ER visit for an adverse reaction for Treatment 2 was also varied 
from zero to five perccnt. Rcsults yielded a cost-effectiveness ratio of 6.43 when the 
probability is increased to 2.5 percent. Accordingly. if the probability of an ER visit 
for an advcrsc reaction were 2.5 percent for Treatment 2. then Treatment 1 would be 
the preferred treatment. 
Increasing the probability of a hospitalization for an attack while on Treatment 
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2 from 0.001 to 0.003 yields a cost-effectiveness ratio of 6.09. Therefore, if the daily 
probability of a hospitalization for an attack is 0.003 for Treatment 2, then Treatment 
1 would be the preferred treatment. Increasing the probability of a hospitalization for 
an adverse reaction while on Treatment 2 from 0.001 to 0.003 yields a cost-
effectiveness ratio of 5.61. Accordingly, if the probability of a hospitalization for an 
adverse reaction were 0.003 for Treatment 2, then Treatment I would be the preferred 
treatment. The results of varying the probability of a hospitalization for an attack from 
zero to 0.5 percent are illustrated in Figure 8. 
Impact of Varying Probability of a Hospitalization for an Attack for 
Treatment 2 
ProbabililyofHospi',,[izationfocanAttack 




Given the apparent equivalent therapeutic efficacy of the three 
pharmacotherapy strategies for moderate adult chronic asthma, the analysis 
presented in Chapter III indicates that a beta2-agonist and a corticosteroid 
(Treatment 2) is the preferable pharmacotherapy of adult chronic moderate 
asthma when utilization of associated hospital services is considered. A beta2-
agonist agent and sustained-release theophylline (Treatment 3) is preferred 
when associated hospital services are not considered. The results are sensitive 
to the probability of an emergency room visit and/or hospitalization associated 
with each treatment. 
B. VALIDIlY 
To accept these results, the validity of the models must be considered. 
Certainly, the models presented here are simple and require several 
assumptions: the time horizon of the process is five years; only one event can 
occur each day; probabilities remain constant; and additional factors such as 
allergies, pollen levels, seasonality effects, concomitant diseases, and patient 
preferences are not modelled. Nevertheless, the models are a reasonable 
approximation of the major cost factors associated with moderate adult chronic 
asthma. 
Any analysis must consider the validity of the data upon which it is 
based. The probabilities used here are the result of meta-analysis. Meta-
analysis methods are not universally accepted. The reviewer must make 
judgements as to which studies are appropriate to include in the review. As a 
result, meta-analysis has been criticized for mixing studies that measure 
"apples" with those that measure "oranges", so that no meaningful results can 
be obtained. Some of the studies summarized in Table 4 were not as well-
controlled as others and dealt with highly selected patients from both children 
and adult populations. The selected studies themselves may be hiased. 
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Published clinical trials may prevail in favor of "significant" or "promising" 
results. Clinical trials which fail to show any treatment differences are less 
likely to be published. Consequencely, conclusions of treatment effects based 
on a review of only published papers may be misleading. However, given that 
the retrospective chart review at Naval Medical Center San Diego (NMCSD) 
yielded a small sample with no data on hospitalizations, a meta-analysis of the 
literature was felt to be superior to ad hoc approaches such as, 
"impressionistic" or "expert opinion". 
Data on costs for the models are also imperfect. While data on costs for 
the medications are readily available, costs associated with an emergency room 
visit are not identifiable at the individual patient level within Navy Medical 
Treatment Facilities (MTFs). That is, if an asthmatic reports to the emergency 
room for an attack, costs for laboratory, X-ray, medications, etc., are not 
recorded in an individual account, but are "pooled" into the Medical Expense 
and Performance Reporting System (MEPRS), designed to reflect all costs of 
services including personnel, direct expenses, and depreciation for "any" 
emergency room visit. The MEPRS cost of an emergency room visit for 
NMCSD of $140.00 was used for all treatments for both the wERJattack" and 
"ERJADR" states/events. This is not necessarily an accurate reflection of the 
costs associated with the different treatments. For example, an asthmatic 
prescribed Treatment 3 may require more laboratory tests, rescue medication, 
etc., than an asthmatic prescribed Treatment 2 or Treatment I, but presently 
there is no method of retrieving this information from MTFs. 
A similar problem exists with the costs of hospitalizations. MEPRS 
costs of inpatient services are aggregated by specialty of care. For example, 
there is an associated cost with the number of occupied bed days of the Internal 
Medicine Ward, Cardiology Ward, Oncology, etc., While it is possible to 
ascertain the length of stay and costs of a hospital admission by the Diagnostic 
Related Group (DRG) through the Retrospective Case-Mix Analysis System 
(RCMAS) , it not known if the patient spent one day in the Intensive Care Unit 
(lCU) and another day in the Allergy Unit. Furthermore, if an asthmatic is 
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admitted to the hospital, the treatment plan the patient was prescribed is not 
recorded in RCMAS. The RCMAS cost at NMCSD associated with DRG code 
097 (Bronchitis or Asthma> 17 years old without complication) of $557 per day 
was used for the "Hospital/attack" state/event for all treatments. This does not 
capture possible differences in lengths of stay/costs associated with each of the 
treatments. However, sensitivity analysis revealed that the models are 
insensitive to changes in single event costs. Therefore, uncertainty about the 
true costs should not impact the models' results. Nevertheless, it is recognized 
that the differences in the cost/effectiveness ratios could be the result of 
impeliect data rather than superior strategies. 
Despite the unreliability of the input parameters, the models presented 
make contributions to two fields. To the modelling audience, they represent the 
results of an attempt to reasonably synthesize important medical and economic 
factors which play crucial roles in the treatment/cost of a chronic disease . To 
the clinician, the models yield valuable information on the comparative 
costleffectiveness of therapy combinations. In addition, the modelling 
techniques applied here invite a number of sensitivity analyses which may 
provide new insights concerning the treatment of asthma. 
C. SUMMARY 
The objective of this thesis was to develop modelling tools for the 
quantitative evaluation of the impact of three different pharmacotherapy 
protocols of chronic moderate adult asthma on hospital services. The methods 
presented are not intended to provide a definitive answer, but rather to 
demonstrate, within the limitations of any probabilistic model, the effects of 
important parameters on the costs and effectiveness of medical treatment plans. 
The techniques outlined here can be easily applied to other diseases such as 
epilepsy and diabetes. 
As resources available for health care become increasingly limited, 
difficult choices among competing uses of health care dollars must be made. 
Currently, the standard of care for medical conditions is influenced by 
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published clinical trials, consensus among clinicians, and formal peer review 
of medical strategies. Analyses such as those presented herein could be 
included as an additional factor in establishing the standard of care. 
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APPENDIX A. GLOSSARY OF TERMS 
Asthma: A disease characterized by reversible airilow obstruction and airway 
hyperresponsiveness. 
Attack: Also termed "exacerbation", Acute or subacute episodes of progressively 
worsening shortness of breath, cough, wheezing, chest tightness, or 
some combination of these symptoms. 
Complication Free interval (eF]): 
The measure of effectiveness for each of the therapies defined as a 
month without an exacerbation or therapy complications requiring 
medical attention. 
Exacerbation: 
Also termed "attack", Acute or subacute episodes of progressively 
worsening shortness of breath, cough, wheezing, chest tightness, or 
some combination of these symptoms. 
Forced Expiratory Volume one second (FEV,): 
The volume of air expired in one second from maximum inspiration. 
Major Adverse Drug Reaction: 
An unwanted medication effect resulting in an emergency room visit or 
hospitalization to treat. 
Minor Adverse Drug Reaction: 
An unwanted medication effect discovered during a routine follow-up 
appointment resulting in a cost to treat. 
Moderate Adult Asthma: 
Individuals eighteen years old or older who have more than two acute 
asthma exacerbations per week with a PEFR or FE\{ decreasing twenty 
to forty percent from their personal best. 
Peak Expiratory F10w Rate (PEFR): 
The maximum flow rate that can be generated during a forced expiratory 
Treatment 1 (Txl) : 
Inhaled beta.-agonist agent (as needed or up to three to four hmes daily) 
and inhaled cromolyn (two puffs four times daily) . 
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Treatment 2 (Tx 2): 
Inhaled beta2-agonist agent (as needed or up to three to four times daily) 
and an inhaled corticosteroid agent (two to four puffs twice dally). 
Treatment 3 (Tx 3): 
Inhaled beta2-agonist agent (as needed or up to three /0 four times daily) 
and sustained release theophylline (dosage must be individualized). 
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APPENDIX B. SAMPLE MAPLE WORKSHEETS 
Results for Treatment ONE (Discrete-Time Discounting Model) 
> with(linalg); 
> 




> (.53,0,0,.47,0,0( , 
> (1,0,0,0,0,0])); 
> 
.99 1 .005 .001 .001 .001 .001 
.999 0 0 .001 
.999 0 0 .001 
p := .37 .63 0 
.53 





discount := .9998594803 
~~r~~~1 
00001011 a 0 0 0 0 





ident6:=0 0 0 1 0 I 
000010
1 000001 
> A:=inverse(evalm(ident[6] . (p*discount))); !032.154070 35.15582957 7.031165914 28.03060177 A :~ ~~~~:~:~~~: !~:~~~:~~~! ~:~~~:~~~~~ ~::~~~~~:~ 029.484025 35.14248122 7.028496244 30.72201501 
029.911170 35.14461665 7.028923329 29.29144939 












1 7.03017522 7.03017565 7.028496244 
7.028923328 
8.030177898 
[40437.71895 40573.52615 40573.25988 41927.41040 41661.09327 40432.86667] 
> p1825:=evalm(p"1825); 
p1825 := 
[.9881532567, .004940766281, .0009881532566, 003940514825, .00098914 14096, 
.000988 1532566] 
[.9881532564 •. 004940766279 •. 0009881532563 • . 003940514824 •. 0009891 41 4093 , 
.0009881532563 ) 
[.9881532564 •. 004940766279, .0009881532563 , .003940514824 , .0009891 414093 , 
.0009881532563] 
{.9881532565, .004940766280, .0009881532564, .003940514824, .0009891 414094, 
.0009881 532564 J 
[.9881532566, .004940766280, .0009881532565 , .003940514825 , .0009891414095 , 
.0009881532565 ] 




> B:=evalm(p1825 *(discount"1825»; 
> 
B:= 
[.7646141532, .003823070764 , .0007646141531 , .003049095255 , .0007653787670 , 
.0007646141531] 
[.7646141529 •. 003823070762, .0007646141529, .003049095254, .0007653787668, 
.0007646141529 ] 
[.7646141529 , .003823070762 •. 0007646141529 , .003049095254 , .0007653787668 , 
.0007646141529] 
[.7646141530, .003823070763, .0007646141529, .003049095254, .0007653787669, 
.0007646141529 ] 
[.7646141531 • . 003823070763, .0007646141530, .003049095255, .0007653787670, 
.00076461415301 
[.7646141532, .003823070764, .0007646141532 • . 003049095255 , ,0007653787671, 
.0007646141532] 
> F:=evalm(ident(6] • B); 
F:= 
[.2353858468. -.003823070764, -.0007646141531 ,-.003049095255, -.00076537117670, 
-.0007646141531 ] 
[-.7646141529, .9961769292, -.0007646141529, -.003049095254 , -.0007653787668 , 
-.0007646141529] 
[-.7646141529, -.003823070762, .9992353858, -.003049095254, -.0007653787668, 
-.0007646141529 ] 
[-.7646141530, -.003823070763, -.0007646141529 •. 9969509047, -.0007653787669, 
-.0007646141529] 
[-.7646141531 ,-.003823070763, -.0007646141530 ,-.003049095255 , .9992346212, 
-.0007646141530] 




[9141.685641 9277.492855 9277.226584 10631.377]0 10365.05996 9136.83336] 
> CostEffectiveness :=(PVfinite[1)/182S)/(p1825[1, 1]); 
Cos/Effectiveness:= 5.069196284 
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Results for Treatment ONE (Continuous-Time Discounting Model) 





> [.37,0,0, .63,0,0], 
> (.53,0,0,.47,0,0], 
> [1 ,0,0,0,0,0]]); 
> 
.99 1 .005 .001 .001 .001 








discount := .9998594803 
h:= .0001405295738 
> ident[6]:=evalm(matrix(6,6,O) +1); 
> evalm(ident[6]); 
> Q;=eva lm( p - ident[6] ); 
idm'6 ~ ; ~ q 1:, 
o 0 0 0 I 
o 0 0 0 0 
o 0 0 0 
I 0 0 0 
o 0 1 
o 0 0 
o 0 0 0 I 
o 0 0 0 0 
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.001 . 
-.009 .005 .001 .OO! .001 .001 
.999 -1 0 .001 
.999 -1 .001 
Q'" 
.3 7 0 -.37 0 
.53 .47 -1 
0 0 -1 
> rl :=evalm(b*ident[6]); 
,.0001405295738,0,0,0, 
,0, .0001405295738 , 0,0,0 1
0001405295738, 0,0,0,0, I 
rl := ,0,0,.0001405295738,0,0 
,0,0,0, .0001 405295738,0
1 
,0,0,0,0 , .0001405295738 
> costs:=([2.16,140,140,557,529,.83]); 
















y:" 028.988979 35.14000667 
7029.4 16067 35.1421418 1 












[ 40434.87070 40570.65878 40570.39253 
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(.9881534515 , .004940767258, .0009881534515 , .003940515605 , .0009891416050 , 
.00098815345151 
[.9881534516, .004940767258, .0009881534515 , .003940515605 , .0009891416050 , 
.0009881534515] 
[.9881534516, .004940767257 , .0009881534515 , .003940515605 , .0009891416050 , 
.0009881534515] 
[ .9881534517, .004940767259, .0009881534518, .0039405154~1 • ,0009891416053, 
.00098815345181 
[,9881534517, .004940767260, .0009881534517 , .003940515483 • ,0009891416053 , 
,0009881534517] 
[.9881534516, ,004940767258 •. 0009881534515, ,003940515605, .0009891416050, 
,00098815345 151 
> rs:=b*1825; 







[,7646143039, .003823071520, .0007646143039, .003049095858 , ,0007653789182 , 
,0007646143039] 
(.7646143040, ,003823071520, ,0007646143039, .003049095858, ,0007653789182, 
,0007646143039 ] 
[,7646143040, ,003823071519. ,0007646143039, .003049095858 •. 0007653789182 , 
,0007646143039] 
[,7646143041 , .003823071521 ,.0007646143041 , .003049095731 •. 0007653789185 , 
,0007(46143041) 
[ .7646143041, ,003823071521, ,0007646143041, ,003049095764, ,000765 3789 185, 
60 
.0007646143041 ] 
[.7646143040, .003823071520 , .0007646143039 , .003049095858 , .0007653789182 , 
.0007646143039] 
[ .2353856961 ,-.003823071520 , -.0007646143039, -.003049095858, -.0007653789182 , 
-.0007646143039] 
[-.7646143040, .9961769285 ,-.0007646143039, -.003049095858 ,-.0007653789182, 
-.0007646143039J 
[-.7646143040, -.003823071519, .9992353857 , -.003049095858 , -.0007653789182, 
-.0007646143039] 
[-.7646 143041 . -.003823071521, -.00076461 43041, .9969509043, -.0007653789185, 
-.0007646143041 ] 
[-.7646143041, -.003823071521, -.0007646143041, -.003049095764 , .99923462 11. 
-.0007646143041 ] 
[ -.7646143040, -.003823071520, -.0007646143039, -.003049095858, .0007653789182, 
.9992353857] 
PV(jinite) :"" 
[9141.036002 9276.824076 9276.557828 10630.51812 10364.23838 9136.18436] 
> CostEffectiveness:=(PV(finite)[1]/1825)/(PS[1, 1]); 
CostEffeCliveness:"" 5.068835051 
61 
Marked Poisson Process Approximation (Treatment 1) 
> with(linalg); 
> r;=evalm(-log( .9998594803»; 
> ert:=exp(-r*1825); 
> 
r := .0001405295738 
ert:= .7737&09373 
> DTx:={D1=140+(.001*D3),D2=140 + (.001*D4),03=557+(.63*03), 
> 04=529+(.47*D3),D5=.83}; 
DTx:= 
{D2 = 140 + .001 D4, D3 = 557 + .63lJ3, D4= 529 +.47 D3, Dl = 140 + .001 D3, D5= .83} 
> solve(DTx,{D1,D2,03,04,05}); 
{D4 = 1236.540541, Dl = 141.5054054, D3 = 1505.405406. D2 = 141.2365405, D5 = .83} 






> psub :=matrix([[O, 0 ,.001 ,0,0], [0,0,0, .001,0],[0,0,.63,0,0], [0,0,.47,0,0] I [0,0,0, 0 ,0]] I; 
~ ~ .001 001 ~ 
pmb= ~ ~:~ 0 ~ 
> evalm(ident[5]); 
> ident[5] :=evalm(matrix(5,5,0) +1); 



















I 0 0 0 0 
o 1 0 0 0 
ident5:= ~ ~ ~ ~ ~ 
o 0 0 0 I 
,~ 0 -.001 ~ 1 0 -.001 0 .37 ~I 0 -.47 0 0 
,002702702702 -.425531914810-12 
.001270270270 .0009999999998 









dprob:=[.5555555555 .1111111111 .1111 11\ 111 . 11\\111 11 1 .1 111111 111] 
> Sdays:=innerprod(si,dprob); 


















c := .3003003002 
d := .2522522522 
e:=.1111 11 1111 
£days;= 1.330882883 




CoslE.ffecliveness := 5. 134676490 
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APPENDIX C. TURBO PASCAL PROGRAMMING CODE 
(* Title : CohortAnalysis 
Author : Lynda M. Race 
Date : 7/12/95 
System : 486/66 with math coprocessor and MS DOS vS.2 
Compiler : TURBO PASCAL for DOS v 7.0 
Description: Program designed to calculate cohort analysis 
_ _________________ 0) 
program CohortAnalysis; 
uses crt; 
type screentype = array[O .. 3999] of byte; 
var screen : screentype absolute $B800;OOOO; {for intra screen} 
x, offset : integer; {to tell intra screen where to go } 
patient_num : integer; 
N _days : integer; 
p_No real; 
p_Ex real; 
p ExHosp real; 
p=ExEr real; 
p _ ExErHosp real; 
p _ ExErHome real; 
p_ADR real; 
p_ADRMin real; 
p _ ADRMaj real; 
p_ADRMajHosp real; 
p_ADRMajEr real; 
p_ADRMajErHosp : real; 












procedure IMAGEDATA; external; 








textbackground (0) ;textcolor(14); 
gotoXY(1,25)j 
writeC Press any key to continue. . 1; 
Press:=; readkey; 
textbackground (1) ;textcolor(14) ; 
clrscr; 
end; 
(*-----------------------------GET DATA-------------------------------_· t ) 





move (pointer(@treeldata)",ptr($B800,O)A,4000); {call tree screen} 












































writer Is this correct? (YIN):); 
readln(press); 








writer Please enter NUMBER OF PATIENTS to simulate: ); 
readln(patient_Num); 
writeln; 




writeC Please enter COST of state HOME: '); 
readln(UHOME); 
writeln; 
writer Please enter COST of state EMERGENCY ROOM/attack: '); 
readln(lJErAttack) ; 
writeln; 
writer Please enter COST of state EMERGENCY RQOM/ADR: '); 
readln(UErADR); 
writeln; 
write, Please enter COST of state HOSPITAl)attack: '); 
readln(UHospAttack); 
writeln; 
writer Please enter COST of state HOSPITAl)ADR: '); 
readln(UHospADR) ; 
writeln; 





writer Is this Correct? (YIN): '); 
readln(press) ; 
until Press in ['Y','y']; 
end; 
(*·.-------------------------Power Function------------------------------*) 




delta: = 1; 





Procedure Results (var P _Num:integer;Util_ Sum_Home3:real; 









COST:=Cum_Util4/ Pt_Cycle_Sum4· N_days3j 
EFF: =CFI4!PT _Cycle _ Sum4j 
writeln( 1 I); 
GOTOXY(Il,15); 
writeln( 11 COST, 11; 
GOTOXY(Il,16); 








writeinCl1 EFFECfIVENESS: II); 
GOTOXY(48,16); 
writeln('11 ',eff:13:5, II); 
GOTOXY(48,17); 
writeln(' I I?; 
Textbackground(l) ; 
CE: =:: (COSTIN _days3)/EFF; 
GOTOXY(3,20); 
textbackground (4) ;textcolor(14); 
wri!eIn(", ~~~~~~~~~~~~~~~~~~ 
GOTOXY(3,21); 
writeln(,11 COST/EFFECTlVENESS RATIO: ',CE:27:2,' 
GOTOXY(3,22); 
wmem( I ~~~~~~~~~~~~~~~~~~~~~~~~) 
textbackground(l) ; 
end; 
Procedure ShowData(var P Num3:integerjI3:integer;Home3:real;ErAttack3:real; 
ErADR3:reiI;HospAttack3:real;HospADR3:real;Minor3:real; 
UtiI Sum3:real;Cum Util3:real; 




Textbackground (4);T extcolor (14) ; 
GOTOXY(3 ,2); 
write1n('FI ~~~~~~~~~~~~~~~~~~~~~~~=n :l 
GOTOXY(3,3); 
writeln Cl. Cycle',' Home',' ERJAttack': ERJADR',' Hasp/Attack',' 




writelnCl1 start ', P num3:7, ' II); 
GOTOXY(3,6); -
writeln(' II', 13:6, Home3:8:0 ,ErAttack3:1O:0 ,ErADR3:1l:0, 




writeinC l1 11; 
GOTOXY(3,9); 
writeln('11 Patient Cum Sum: Cum Cost: II'); 
GOTOXY(3,]0); 
writeln(' II , ,Pt_Cycle_Sum2:21:0, Cum_Util3:38:0: 1'); 
GOTOXY(3,1l); 
writein(1  11; 
GOTOXY(3,]2); 
wri1eln(" ' ) 
textbackground (1) ; textcoior(14); 
results(p _ num3,Utit Sum_Hame2,Cum _ UtiI3,Pt_ Cycle_Sum2,CFI2 ,N _ days2); 
end; 
e-------------------------·-------CyCLE----------------------------------.) 
Procedure Cycle(var P _num:integer;N_daysl :integer; 




pNo:real; U Home:real;U ErAttackreal;U ErADR:real; 
- - -
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Minor 1 :real; 
Hosp)attack:real; 
Pt_Cycle_Sum:reaJ; 









Util Sum Homel: = O; 
C Utill:;O; 
dlScQunt:=O; 
Home: = P num*pNo; 
ErAttack: ;;;' P num*pEx·pExEr*pExErHome; 
HospAttack:: (p _num*pEx*pExHosp) + (P _Nurn*pEx*pExEr·pExErHosp); 
Minor:= P_num·pADR·pADRMin; 
HospADR: = (P _ num·pADR*pADRMaj*pADRMajHosp) + (P _ num*pADR*pADRMaj* 
71 
pADRMajEr"'pADRMajErHosp); 
ErADR: = (p _ num "'pADR*pADRMaj'"pADRMAjEr*pADRMAjERHome); 








Util_Sum2:= (HomeZ"'U_Home)"'discount + 
(ErAttack2*U_ErAttack)*discount + 
(HospAttackl*U_HospAttack)'"discount +. 
(J\1inor2"'U _ Minor)"'discount + 
(HospADR2"'U_HospADR)"'discount + 
(ErADR2"'U_ErADR)"'discountj 
Cum_Util2:= (UtitSum2 + C_Utill); 
Util_Sum_Home:=(HomeZ"'U_Home) + Util_Sum_Homel; 
Pt_Cycle_Sum:=(HomeZ) + (ErAttack2) + 
(HospAttack2 ) + (J\1inor2) + 
(HospADR2) + (ErADR2) + Pt_Cycle_Sumlj 
CFl:=Home2 + CFIl; 
Home_l:=HomeZj 
Er lAttack:=ErAttack2; 
Hasp _lAttack: ... HospAttackl; 
Minor 1: = MinorZ; 
HospjADR: =HospADR2; 
Er_lADR:=ErADR2; 
Home:=(Home_l*pNo) + (Er_lAttack*pExErHome) + 
(Er_lADR"'pADRMajErHome) 
+ (Hosp_lADR*0.53) + (Hosp_lAttack*O.37) + (J\1inor_l); 
ErAttack: = (Home l*pEx*pExEr); 
ErADR:=(Home i*pADR"'pADRMaj*pADRMajEr)j 
HospADR: = (Home_l*pADR*pADRMaj"'pADRMajHosp) + 
(Er_lADR*pADRlviAjHosp); 
HospAttack: = (Home 1 *pEx'"pExHosp) + 
(Er _lAttack*pExERHosp) + (Hosp _lAttack*O.63) 
+ (Hosp IADR*O.41); 
Minor: = (Home _1 *pADR*pADRMin); 
C_utill:=Cum_utilZ; 
72 
Util Sum Homel: = Util Sum Home; 
Pt_Cycle: Suml: =Pt_Cycle_Sum; 
CFIl :=CFI; 
clrscr; 









textbackground(1 ) :textcolor(14); 
Get Data; 
Cycle (patient_oum,N_days, 




textbackground(l) ;textco!or (15) ; 
GOTOXY(16,24); 
write (Do you want to run another simulation? (YIN): I; 
readln(Press); 
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